GlassScriptPhysician profile
Tamjeed Ahmed
NPI 1235420316
$11,171.29
in general payments reported to CMS, 2019-2025
59 companies · $6,679 in 2025
The $6,679 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $312 · 2021: $11.92 · 2022: $462 · 2023: $1,429 · 2024: $1,965 · 2025: $6,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,494 · Consulting Fee: $2,400 · Travel and Lodging: $1,125 · Education: $53.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,494.29 |
| Consulting Fee | $2,400.00 |
| Travel and Lodging | $1,124.86 |
| Education | $53.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Partner Therapeutics, INC. | $3,709.82 | 2025 | Bizengri |
| Novartis Pharmaceuticals Corporation | $522.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $490.77 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $429.24 | 2020-2025 | Tagrisso, Lynparza, Calquence |
| Pfizer INC. | $419.39 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $371.80 | 2023-2025 | Libtayo |
| Eisai INC. | $335.96 | 2020-2025 | |
| Daiichi Sankyo INC. | $333.82 | 2022-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $329.17 | 2022-2025 | Talvey, Erleada, Tecvayli |
| Abbvie INC. | $295.36 | 2022-2025 | Venclexta |
| Celgene Corporation | $257.94 | 2022-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $234.85 | 2020-2025 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $211.99 | 2024 | Onivyde, Somatuline Depot |
| Genentech USA, INC. | $192.48 | 2019-2025 | Perjeta, Phesgo, Polivy |
| Jazz Pharmaceuticals INC. | $184.47 | 2022-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $183.91 | 2023-2025 | Fotivda |
| Amgen INC. | $166.38 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Takeda Pharmaceuticals U.S.A., INC. | $153.34 | 2019-2025 | Iclusig, Ninlaro, Alunbrig |
| Taiho Oncology, INC. | $148.26 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $140.31 | 2023-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $138.25 | 2020-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $129.77 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Pharmacyclics LLC, An Abbvie Company | $114.82 | 2019-2023 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $108.19 | 2024-2025 | Monoferric, Cosela |
| Genzyme Corporation | $104.96 | 2023-2025 | |
| Astellas Pharma US INC | $101.93 | 2019-2025 | Vyloy, Xtandi |
| Gilead Sciences, INC. | $98.16 | 2021-2023 | Trodelvy |
| Tersera Therapeutics LLC | $96.36 | 2022-2025 | Zoladex, Xermelo |
| Morphosys, US INC. | $94.35 | 2022-2023 | Monjuvi |
| Exelixis INC. | $93.72 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $88.24 | 2023-2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $79.49 | 2022-2025 | |
| Pharmaessentia USA Corporation | $69.60 | 2024-2025 | Besremi |
| Puma Biotechnology, INC. | $57.14 | 2024-2025 | |
| Emd Serono, INC. | $54.97 | 2023-2025 | Tepmetko |
| Beone Medicines USA, INC. | $49.91 | 2025 | Tevimbra, Brukinsa |
| Genmab U.S., INC. | $46.96 | 2024-2025 | Epkinly |
| G1 Therapeutics, INC. | $42.57 | 2022-2023 | Cosela |
| Seagen INC. | $41.01 | 2020-2023 | Padcev |
| Lilly USA, LLC | $39.53 | 2023 | Retevmo, Jaypirca, Verzenio |
| Array Biopharma INC | $35.41 | 2020-2025 | Xalkori, Braftovi, Mektovi |
| Adaptive Biotechnologies Corporation | $32.73 | 2025 | Clonoseq |
| Incyte Corporation | $32.06 | 2019-2025 | Niktimvo, Jakafi |
| Rigel Pharmaceuticals, INC. | $31.94 | 2023-2024 | Tavalisse, Rezlidhia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.75 | 2024 | Gilotrif |
| Springworks Therapeutics, INC. | $27.44 | 2025 | |
| Stemline Therapeutics INC. | $25.83 | 2025 | Orserdu |
| Verastem, INC. | $21.64 | 2025 | Avmapki Fakzynja Co-Pack |
| Adc Therapeutics America, INC. | $21.46 | 2025 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Organon LLC | $20.14 | 2024 | |
| Iovance Biotherapeutics, INC. | $19.21 | 2025 | Amtagvi |
| Sumitomo Pharma America, INC. | $19.00 | 2024 | Orgovyx |
| Azurity Pharmaceuticals, INC. | $18.80 | 2025 | Danziten |
| Shield Therapeutics INC | $16.95 | 2025 | |
| Foundation Medicine, INC. | $13.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.49 | 2020 | |
| Dova Pharmaceuticals | $11.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamjeed Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.